Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
- Indications Hyperlipoproteinaemia type II
- Focus Biomarker; Registrational; Therapeutic Use
- 24 Jul 2006 Status change
- 06 Nov 2005 New trial record.